Floatz logo

Ipilimumab

Recurrent Rhabdomyosarcoma

Children's National Research Institutemonoclonal_antibodyPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

58 Active assets in the Recurrent Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Eisai Inc.
Phase 2BBB
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
Cixutumumab
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →